311 related articles for article (PubMed ID: 25671649)
1. Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: the IMMUNEF clinical trial.
Soria A; Trabattoni D; Squillace N; Rainone V; Gnudi F; Clerici M; Gori A; Bandera A
PLoS One; 2015; 10(2):e0117118. PubMed ID: 25671649
[TBL] [Abstract][Full Text] [Related]
2. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067.
D'Amico R; Yang Y; Mildvan D; Evans SR; Schnizlein-Bick CT; Hafner R; Webb N; Basar M; Zackin R; Jacobson MA
J Clin Immunol; 2005 Mar; 25(2):106-15. PubMed ID: 15821887
[TBL] [Abstract][Full Text] [Related]
3. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
4. Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy.
Routy JP; Angel JB; Patel M; Kanagaratham C; Radzioch D; Kema I; Gilmore N; Ancuta P; Singer J; Jenabian MA
HIV Med; 2015 Jan; 16(1):48-56. PubMed ID: 24889179
[TBL] [Abstract][Full Text] [Related]
5. Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.
Habtewold A; Amogne W; Makonnen E; Yimer G; Riedel KD; Ueda N; Worku A; Haefeli WE; Lindquist L; Aderaye G; Burhenne J; Aklillu E
J Antimicrob Chemother; 2011 Oct; 66(10):2350-61. PubMed ID: 21846671
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and determinants of T-cell phenotype normalization in HIV-1-infected individuals receiving long-term antiretroviral therapy.
Ndumbi P; Gillis J; Raboud J; Cooper C; Hogg RS; Montaner JS; Burchell AN; Loutfy MR; Machouf N; Klein MB; Tsoukas C;
HIV Med; 2014 Mar; 15(3):153-64. PubMed ID: 24304582
[TBL] [Abstract][Full Text] [Related]
7. Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.
Lim A; Tan D; Price P; Kamarulzaman A; Tan HY; James I; French MA
AIDS; 2007 Jul; 21(12):1525-34. PubMed ID: 17630546
[TBL] [Abstract][Full Text] [Related]
8. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study.
; Carey D; Puls R; Amin J; Losso M; Phanupak P; Foulkes S; Mohapi L; Crabtree-Ramirez B; Jessen H; Kumar S; Winston A; Lee MP; Belloso W; Cooper DA; Emery S
Lancet Infect Dis; 2015 Jul; 15(7):793-802. PubMed ID: 25877963
[TBL] [Abstract][Full Text] [Related]
10. Baseline Naive CD4+ T-cell Level Predicting Immune Reconstitution in Treated HIV-infected Late Presenters.
Guo FP; Li YJ; Qiu ZF; Lv W; Han Y; Xie J; Li YL; Song XJ; Du SS; Mehraj V; Li TS; Routy JP
Chin Med J (Engl); 2016 Nov; 129(22):2683-2690. PubMed ID: 27824000
[TBL] [Abstract][Full Text] [Related]
11. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.
Goicoechea M; Smith DM; Liu L; May S; Tenorio AR; Ignacio CC; Landay A; Haubrich R
J Infect Dis; 2006 Jul; 194(1):29-37. PubMed ID: 16741879
[TBL] [Abstract][Full Text] [Related]
12. Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications.
Negredo E; Massanella M; Puig J; Pérez-Alvarez N; Gallego-Escuredo JM; Villarroya J; Villarroya F; Moltó J; Santos JR; Clotet B; Blanco J
Clin Infect Dis; 2010 May; 50(9):1300-8. PubMed ID: 20367229
[TBL] [Abstract][Full Text] [Related]
13. Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
Dyrhol-Riise AM; Voltersvik P; Røsok BI; Olofsson J; Asjö B
AIDS Res Hum Retroviruses; 2000 Feb; 16(3):191-201. PubMed ID: 10710207
[TBL] [Abstract][Full Text] [Related]
14. Impaired Th17 polarization of phenotypically naive CD4(+) T-cells during chronic HIV-1 infection and potential restoration with early ART.
DaFonseca S; Niessl J; Pouvreau S; Wacleche VS; Gosselin A; Cleret-Buhot A; Bernard N; Tremblay C; Jenabian MA; Routy JP; Ancuta P
Retrovirology; 2015 Apr; 12():38. PubMed ID: 25924895
[TBL] [Abstract][Full Text] [Related]
15. HIV Reservoir Decay and CD4 Recovery Associated With High CD8 Counts in Immune Restored Patients on Long-Term ART.
Zhang LX; Jiao YM; Zhang C; Song JW; Fan X; Xu RN; Huang HH; Zhang JY; Wang LF; Zhou CB; Jin L; Shi M; Wang FS
Front Immunol; 2020; 11():1541. PubMed ID: 32793212
[No Abstract] [Full Text] [Related]
16. Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.
Okulicz JF; Le TD; Agan BK; Camargo JF; Landrum ML; Wright E; Dolan MJ; Ganesan A; Ferguson TM; Smith DM; Richman DD; Little SJ; Clark RA; He W; Ahuja SK
JAMA Intern Med; 2015 Jan; 175(1):88-99. PubMed ID: 25419650
[TBL] [Abstract][Full Text] [Related]
17. Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Gray CM; Schapiro JM; Winters MA; Merigan TC
AIDS Res Hum Retroviruses; 1998 May; 14(7):561-9. PubMed ID: 9591710
[TBL] [Abstract][Full Text] [Related]
18. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
19. [Impact of etiotropic therapy on the immune status of patients with HIV infection and tuberculosis].
Zimina VN; Kravchenko AV
Ter Arkh; 2015; 87(11):37-41. PubMed ID: 26821414
[TBL] [Abstract][Full Text] [Related]
20. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
Wu H; Connick E; Kuritzkes DR; Landay A; Spritzler J; Zhang B; Spear GT; Kessler H; Lederman MM;
AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1231-40. PubMed ID: 11559422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
